| Patient | Judy Garland |
|---|---|
| Date of birth | 1993-06-10 |
| Identifiers | MRN HR-ML005-SYN; SSN (made up) 000-05-6127 |
| Document date | 2026-08-31 |
| Author | Margaret Ellsworth-Diaz, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Ten-week review: phenobarbital taper, four weeks after stopping dextroamphetamine. [S]
Ms. Garland returns six weeks after her four-week review. She took the last dextroamphetamine tablet four weeks ago. For about two weeks afterwards she was tired, slept more and felt flat, and then her energy returned; she has had occasional urges to take a pill before rehearsals and has not acted on them. Her appetite has come back and she eats three meals on most days. She has gained 1.3 kg since the last visit, and she worries about it; we talked about it without a target. The step to 64.8 mg of phenobarbital went smoothly. Two weeks ago, at the sick visit for laryngitis, the next step was paused; her voice recovered within six days and she is back to singing. She sleeps about six hours on most nights. She saw the dietitian last week. Her mood is better. [S]
| Element | Detail |
|---|---|
| Dextroamphetamine | Stopped four weeks ago; two weeks of tiredness, then better |
| Phenobarbital | 64.8 mg a day for four weeks; step paused at the sick visit |
| Laryngitis | Resolved in six days |
| Sleep | About six hours; Insomnia Severity Index 13 |
| Mood | PHQ-9 9; GAD-7 8 |
| Weight | 48.9 kg; three meals on most days |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy back to her usual; no fever |
| Ears, nose, mouth, and throat | Negative | Voice recovered; no sore throat |
| Neurological | Negative | No tremor or seizure-like episodes |
| Psychiatric | Positive | Occasional urges to take a stimulant before rehearsals; mood better; no thoughts of suicide or self-harm |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Secobarbital 100 mg oral capsule, two capsules (200 mg) at bedtime; prescribed elsewhere for years; continued by this clinic at the verified dose, seven days at a time, until a supervised withdrawal is planned with addiction medicine | Two capsules at bedtime; no extra doses | Oral route | 2026-06-22 to 2026-07-06 | completed | S |
| Dextroamphetamine 10 mg oral tablet, one tablet each morning; no extra doses; prescribed elsewhere for weight and energy | One tablet each morning | Oral route | 2026-06-22 to 2026-07-20 | completed | S |
| Dextroamphetamine 5 mg oral tablet, one tablet each morning for two weeks, then stop | One tablet each morning for two weeks, then stop | Oral route | 2026-07-20 to 2026-08-03 | completed | S |
| Sertraline 25 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-06-22 to 2026-06-29 | completed | S |
| Sertraline 50 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-06-29 | active | S |
| Phenobarbital 32.4 mg oral tablet, one tablet three times daily (97.2 mg a day), started in hospital in place of secobarbital | One tablet three times daily | Oral route | 2026-07-06 to 2026-07-20 | completed | S |
| Phenobarbital 16.2 mg oral tablet on a written taper schedule in two or three divided doses: 81 mg a day from the four-week visit, lowered by 8.1 to 16.2 mg about every two weeks and paused when needed; dispensed two weeks at a time | Per the written taper schedule, in two or three divided doses | Oral route | 2026-07-20 | active | S |
| Medroxyprogesterone acetate 150 mg/mL injection, 150 mg into the muscle every 13 weeks | 150 mg intramuscularly every 13 weeks | Intramuscular route | 2026-06-22 | active | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for throat pain, no more than 3,000 mg a day, for up to five days | Two tablets every 6 hours as needed, up to 3,000 mg a day | Oral route | 2026-08-17 to 2026-08-22 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-08-31 | Body height | 151 | cm | S |
| 2026-08-31 | Body weight | 48.9 | kg | S |
| 2026-08-31 | Body mass index (BMI) [Ratio] | 21.4 | kg/m2 | S |
| 2026-08-31 | Systolic blood pressure | 112 | mm[Hg] | S |
| 2026-08-31 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-08-31 | Heart rate | 72 | /min | S |
| 2026-08-31 | Respiratory rate | 14 | /min | S |
| 2026-08-31 | Body temperature | 36.7 | Cel | S |
| 2026-08-31 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-08-31 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 9 | {score} | S | ||
| 2026-08-31 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 8 | {score} | S |
Vital signs recorded on 2026-08-31; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 112/72, pulse 72; weight 48.9 kg, BMI 21.4 |
| Ears, nose, mouth, and throat | Voice clear; throat normal |
| Neurological | No tremor or nystagmus |
| Psychiatric | Brighter; no signs of sedation or withdrawal |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Sedative, hypnotic, or anxiolytic use disorder (barbiturate), moderate, with physiological dependence; began with sleeping pills given in adolescence; synthetic modern episode linked to her documented lifelong dependence on prescribed sleeping pills | active | confirmed | F13.20 | S — Synthetic modern coding. Tolerance and withdrawal are not counted toward the diagnosis for a medicine taken under medical supervision; five other criteria are met. Person-first language; not a claim about her real diagnosis. |
| Stimulant use disorder (prescribed amphetamine), mild; began with stimulants given in adolescence for weight and energy; synthetic modern episode linked to her documented pep pills | active | confirmed | F15.10 | S — Synthetic modern coding; DSM-5-TR mild stimulant use disorder maps to F15.10. Tolerance and withdrawal are not counted for a supervised prescription. |
| Chronic insomnia disorder, long-standing, with sleep tied to sleeping pills since adolescence | active | confirmed | G47.00 | S — Synthetic modern diagnosis anchored to the documented sleeping pills. |
| Contraception three months after childbirth while starting an enzyme-inducing drug: injectable progestin chosen because barbiturates, including any used for the withdrawal, weaken contraceptive pills, patches, rings and implants | active | confirmed | Z30.013 | S — Synthetic contraception need; the birth is documented. |
| Major depressive disorder, single episode, moderate, with anxious distress; Mood Disorder Questionnaire negative and no history of mania or hypomania | active | confirmed | F32.1 | S — Synthetic modern diagnosis; not a claim about her real mood. The roster's bipolar disorder lead is not supported by the sources read and is not used. |
| Acute laryngitis, probably viral, during rehearsals, treated with voice rest and supportive care; resolved | resolved | confirmed | J04.0 | S — Synthetic acute illness; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Barbiturate dose, adherence, extra doses, and withdrawal signs (tremor, sweating, pulse, sleep, seizure warning signs) | Every visit | Completed today | 64.8 mg a day; no withdrawal signs |
| Medication safety | Taper pace | Reductions of no more than about 20% every two weeks, slower toward the end; pause for symptoms, illness or a major performance | Completed today | 81 to 64.8 mg two weeks after the first step; paused at the sick visit; 64.8 to 56.7 mg today (12.5%) |
| Medication safety | Prescription drug monitoring program check | Before every controlled-substance prescription | Completed today | Only this clinic's prescriptions; no opioid from the sick visit |
| Laboratory | Urine drug testing, explained as part of care | At the start, after the change to phenobarbital, and periodically during the taper | Up to date | Last at the four-week visit; next at four months |
| Medication safety | Limited dispensing, locked storage and take-back of unused capsules | Seven days at first, then two weeks at a time | Completed today | Two-week supplies; locked box |
| Medication safety | Mood, sleep, energy and appetite after stopping the stimulant | Weekly for the first month after stopping, then each visit | Completed today | Two weeks of tiredness and flat mood, then better; appetite back; occasional urges |
| Examination | Electrocardiogram | Before continuing a stimulant | Not indicated | Stimulant stopped |
| Survey | CBT for insomnia, sleep diary and Insomnia Severity Index | Weekly CBT-I sessions; sleep diary and index at each visit | Completed today | Weekly sessions; Insomnia Severity Index 13 |
| Medication safety | New hypnotic (benzodiazepine, Z-drug, trazodone or antihistamine) | Not recommended as a replacement | Not indicated | No new hypnotic |
| Survey | Depression (PHQ-9) | At least monthly during acute treatment | Deferred | PHQ-9 9 today, six weeks after the last score, longer than the monthly check advised; the sick visit did not repeat it. No harm resulted: her weekly therapist saw no worsening and today's score is lower. Corrective action: PHQ-9 at the preventive visit and monthly after that |
| Survey | Anxiety (GAD-7) | With each PHQ-9 while anxiety is treated | Completed today | GAD-7 8 |
| Medication safety | Sertraline adherence and side effects | Two weeks after starting or changing the dose, then each visit | Completed today | 50 mg daily; no side effects |
| Survey | Suicide-risk review (C-SSRS screen since the last visit), safety plan, means safety and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | C-SSRS screen negative since the last visit; the 988 Suicide & Crisis Lifeline in her phone |
| Examination | Weight, meals and disordered-eating screen, without a weight target | Every visit | Completed today | Weight 48.9 kg, BMI 21.4; three meals on most days; discussed without a target |
| Referral | Dietitian visit | Within a month of intake | Completed today | Seen last week by the second dietitian; plan for meals around rehearsals |
| Medication safety | Contraception that phenobarbital does not weaken | Medroxyprogesterone every 13 weeks | Due | Second injection due at the preventive visit in four weeks |
| Medication safety | Naloxone | Reassess at every visit and whenever an opioid is prescribed | Not indicated | No opioids prescribed or used; codeine was avoided at the sick visit |
| Self-management | Alcohol and other sedatives | Every visit | Completed today | No alcohol; no other sedatives or sleep aids |
Goal progress:
Guideline basis: Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025); The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024); Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline (2017); Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians (2016); U.S. Medical Eligibility Criteria for Contraceptive Use, 2024 (2024); Prescription Drug Monitoring Programs (PDMPs) (2026); Depression and Suicide Risk in Adults: Screening (2023); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)
Follow-up: Nurse phone check before each taper step. Preventive visit in four weeks with the PHQ-9 and the second contraceptive injection. Four-month review in eight weeks with laboratory checks. Next scheduled visit 2026-09-28: periodic adult preventive visit. [S]